Loading your page…
International journal of pharmaceutics: X
By Luo ZY, Han RJ, Guo TJ and 11 others.
Ward brings these articles into the same app as your cards and questions. One free account for Ward, Suture, Osler and Prognia.
The blood-brain barrier (BBB) severely impedes neuroprotective agent delivery to the brain in Parkinson's disease (PD). Although gastrodin (Gas) possesses neuroprotective properties, its efficacy is limited by poor BBB permeability. This study aimed to develop a brain-targeted extracellular vesicle (EV) delivery system for Gas and elucidate its neuroprotective mechanisms.
A brain-targeted EV delivery system was developed using mesenchymal stem cell-derived EVs modified with lactoferrin (Lf). Gas was loaded into Lf-EVs via sonication to construct Lf-EVs-Gas nanocomplexes. The nanocomplexes were characterized by transmission electron microscopy, western blotting, and nano-flow cytometry. Trans-Barrier transport was evaluated using an in vitro Transwell BBB model (hCMEC/D3 cells), while therapeutic efficacy and biodistribution were assessed in an MPTP-induced PD mouse model.
Lf-EVs-Gas exhibited a typical cup-shaped morphology, with a mean size of 79.08 nm and a drug loading efficiency of 47.08 ± 4.63%. Lf functionalization significantly enhanced BBB transport, achieving a brain Gas concentration of 10.34 ± 2.7 ng/g in PD mice versus undetectable levels for free Gas. The targeted system demonstrated superior brain accumulation versus non-targeted vesicles. In 6-OHDA-treated SH-SY5Y cells and MPTP-induced PD mice, the system upregulated tyrosine hydroxylase, reduced α-synuclein aggregation, inhibited neuronal apoptosis, and improved motor function. Mechanistically, these protective effects of Lf-EVs-Gas were associated with activation of PINK1-related mitophagy, as evidenced by elevated LC3-II/LC3-I ratio and increased TOMM20/LC3 colocalization.
Lf-EVs-Gas enhanced the brain delivery of Gas and produced neuroprotective effects in cellular and mouse toxin-based models of PD. These effects were associated with the activation of PINK1-related mitophagy, supporting Lf-modified EVs as a promising brain-targeted delivery platform for Gas. Further studies establishing mechanistic causality, long-term safety, and efficacy in progressive PD models are warranted.
Published in International journal of pharmaceutics: X. The abstract is shown as published and remains the work of its authors; read the full article at the source.
Prognia lists this article for reference and education. It is not medical advice. Always read the original and follow current guidelines and local protocols before acting on it.
